Yidu Tech Inc.
醫渡科技有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 2158)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

The board (the "**Board**") of directors (the "**Directors**") of Yidu Tech Inc. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 September 2025 (the "**Reporting Period**"), together with the comparative figures for the six months ended 30 September 2024. The results have been reviewed by the Company's audit committee.

In this announcement, "we", "us", and "our" refer to the Company and where the context otherwise requires, the Group.

FINANCIAL HIGHLIGHTS

	Six months ended 30 September		
	2025	2024	Change (%)
	(RMB'000, except percentages)		
Revenue	**358,105**	329,448	8.7%
— Big Data Platform and Solutions	**153,180**	133,670	14.6%
— Life Sciences Solutions	**138,253**	144,617	(4.4%)
— Health Management Platform and Solutions	**66,672**	51,161	30.3%
Gross profit	**134,027**	117,350	14.2%
Operating loss	**(15,719)**	(54,273)	(71.0%)
Loss for the period	**(15,760)**	(56,362)	(72.0%)

The Board did not recommend the distribution of an interim dividend for the six months ended 30 September 2025.

BUSINESS REVIEW

As the global medical AI industry enters a critical phase of systematic integration and large-scale implementation, policy guidance and technological innovation are jointly driving the continuous expansion of industry boundaries. With AI being incorporated into national-level systematic initiatives, the integration pathways of medical AI with public services, governance, and industrial innovation are becoming increasingly clear, paving the way for a leap in the penetration rate of AI in medical scenarios. Propelled by multiple forces, medical large language models are no longer confined to optimizing efficiency in isolated tasks but are progressively building intelligent systems that support the entire diagnostic and treatment process, the full drug lifecycle, and comprehensive health management. This will unlock greater value in enhancing the utilization efficiency of medical resources and overcoming bottlenecks in research translation. As a company deeply entrenched in the field of medical intelligence, Yidu Tech will leverage its "healthcare — pharmaceuticals — insurance — patient" ecosystem to accelerate the deep integration of large language model technologies with real-world scenarios, actively participate in building inclusive, efficient, and collaborative medical AI infrastructure, to consistently lead innovation as the industry transitions from building technological capabilities to systematic empowerment.

We have consistently maintained our focused strategy, continued to deepen our engagement with core clients and key businesses to steadily enhance profitability. Against a favorable industry policy backdrop, market demand has been effectively stimulated, leading to significant growth in our order volume. During the six months ended 30 September 2025, the Group's total revenue reached RMB358.1 million, representing a year-on-year increase of 8.7%. Such increase was primarily driven by expanded business opportunities resulting from policy tailwinds. Meanwhile, through continuous optimization of internal operations and strengthened synergies across business segments, we effectively control operating costs and improve resource utilization efficiency. During the Reporting Period, the loss for the period of the Group narrowed to RMB15.8 million, a year-on-year decrease of 72.0%. In terms of cash flow, net cash outflow from operating activities was reduced by 56.0% year-on-year through enhanced fund management and utilization efficiency. As of 30 September 2025, the Group's total cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balances, and deposits amounted to RMB2,099.3 million, with ample cash reserves. These developments underscore the sustained competitiveness of our technologies and products in the current industry landscape, while further strengthening our foundation for capturing future market opportunities and achieving high-quality growth.

As the Group's core algorithm engine, YiduCore continued to advance the development and training of a large language model specialized in the medical vertical domain during the Reporting Period. Training was carried out based on over 500 billion high-quality tokens, nearly 7.0 billion authorized medical records from over 1.3 billion patient visits were processed and analyzed, and a dataset system covering over 98 specialized diseases was established. Our model not only secured the championship in the "Medical NLP Code Automatic Generation Evaluation" and was honored with "Best Paper Award" at the 11th China Health Information Processing Conference (CHIP 2025), but also claimed the first prize in the Healthcare Track of the Jiangxi Regional Finals of 2025 "Data Elements ×" Competition. As a key ecological partner of the National AI Application Pilot Base in the Medical Field of Beijing, YiduCore has achieved large-scale deployment in healthcare, pharmaceutical, health insurance and other sectors through a "unified foundation supporting multiple applications (一底座多應用)" model, fully implementing solutions covering the entire "healthcare-pharmaceuticals-insurance-patient" scenario.

During the Reporting Period, we have provided solutions to 127 top hospitals in China and 44 regulators and policymakers, cumulatively covering over 10,000 hospitals. Driven by the dual engines of "Data Factor × AI Technology", we continuously strengthened our intelligent data foundation and accelerated the scalable deployment of intelligent applications. Our large language model technology has assisted several hospitals in upgrading their data governance and research platforms. Clinical research has deepened and expanded across multiple disciplines, including oncology, respiratory diseases, and traditional Chinese medicine. The product portfolio of physician Copilot covers the entire diagnostic and treatment process, with over 50,000 deployments in a single hospital. Our AI middleware further supports innovative applications in multiple hospitals and medical aesthetics scenarios. During the Reporting Period, the number of life science clients we serve has reached 88. Among the top 20 multinational pharmaceutical companies, 17 are our clients. We have made significant breakthroughs in cutting-edge fields such as pediatric rare diseases and cell therapy and have successfully supported the accelerated approval of multiple pioneering drugs. In the Health Management Platform and Solutions segment, we maintained our advantageous position in core cities, and we were the main operating platform for Shenzhen Hui Min Bao (深圳惠民保) for three consecutive years and also the main operating platform for Beijing Hui Min Bao (北京惠民保) for five consecutive years, with the number of the insured in Shenzhen Hui Min Bao (深圳惠民保) recording new high during the Reporting Period, reaching 6.15 million, and the cumulative number of the insured reached 18 million in a three-year period. Brand loyalty is steadily strengthening. The number of active users who completed at least one transaction on our health management platform surpassed 22 million.

YiduCore

YiduCore, our "AI Medical Brain", serves as the core algorithmic engine of Yidu Tech, to continuously enhance medical insights and algorithmic intelligence through a reinforced closed-loop system of "data-driven algorithms, algorithm-empowered scenarios and scenario-enhanced data", thereby establishing a mutually reinforcing flywheel effect between "technology — application — data" that forms our competitive barrier. YiduCore simulates the human physician's brain to autonomously learn the entire process through which physicians operate from information collection and deep reasoning to decision-making, and to emulate their cognitive patterns and logical approaches in disease diagnosis, treatment selection, and public health management. This enables its performance across diverse scenarios to closely align with real-world physician behavior.

As the fundamental cornerstone of algorithmic performance, data underpins YiduCore's capabilities. To date, YiduCore has processed and analyzed nearly 7.0 billion authorized medical records from over 1.3 billion patients. In response to long-standing challenges in medical research such as data silos, inefficient research processes, and slow translation of findings, we have established an intelligent research ecosystem spanning "hospital-wide, specialty-specific, alliance-based and beyond-hospital" scopes. Leveraging high-quality and structured data elements, we comprehensively empower medical research. To date, the Group has supported the creation of 21 specialized disease datasets across different therapeutic areas, with the disease knowledge graph now almost covering all known diseases and the specialized disease repository expanding to 98 categories, providing deep knowledge support for clinical research.

The research and development of AI models focus on key breakthroughs in the medical vertical domain. The Group has prioritized the construction of a large medical language model with 70B parameters, trained on a corpus of over 500 billion high-quality, meticulously cleaned and proportionally balanced TOKEN (covering medical, general, Chinese, and English data), and completed fine-tuning on tens of millions of samples. The model's performance has achieved significant multi-dimensional improvements in clinical scenarios: by incorporating a staging rule knowledge base, anatomical knowledge graphs, and physicians' thinking experiences, combined with an AI reflection and self-validation mechanism, the accuracy of tumor staging has been notably enhanced, reaching the professional level of chief physicians. Meanwhile, addressing the industry pain point of "hallucinations" in large medical language models, we have controlled the incidence of hallucinations at a low level with Agent technology through model training optimization, knowledge fusion enhancement, supervision mechanism refinement and engineering control strengthening. Additionally, we independently developed the MED-RAG architecture, enabling precise retrieval and efficient reasoning of complex medical knowledge. Notably, the Group has made significant progress in lightweight model applications. The performance of small language models combined with intelligent agent technology is approaching that of large-parameter models + intelligent agents, effectively reducing hardware computational requirements and providing cost advantages for scalable technology deployment.

On the computing power front, we have successfully achieved full-stack adaptation of both domestic and international high-end chips in China's healthcare vertical sector. We have further expanded support for GPUs such as those from Huawei while continuously enhancing the computational efficiency of the NVIDIA platform. In terms of algorithms, we have received industry-wide professional recognition. At the 2025 "Data Factor X" competition's Jiangxi sub-competition, YiduTech was awarded first prize in the healthcare track, meanwhile, the AI middleware participated in the intelligent agent R&D evaluation conducted by the China Academy of Information and Communications Technology (CAICT), reaching the third level, reaffirming our strength in the field of medical data intelligence. Recently, leveraging its pioneering research in advanced algorithms, the Group won the championship in the "Medical NLP Code Automatic Generation Evaluation" and was honored with "Best Paper Award" at the 11th China Health Information Processing Conference (CHIP 2025), demonstrating our comprehensive strength in both technology and academia within the AI-driven healthcare field. Furthermore, in the endeavor to establish the National AI Application Pilot Base in the Medical Field of Beijing, Yidu Tech, as a key ecological partner, has actively engaged in platform construction and scenario-based innovation, promoting the implementation of multiple key projects.

In terms of application, YiduCore has achieved scaled implementation across multiple business domains, including healthcare, pharmaceuticals, and health insurance. After a decade of accumulation, we have progressively established a "unified foundation supporting multiple applications (一底座多應用)" model, fully realizing comprehensive solutions for the "healthcare-pharmacy-insurance-patient" ecosystem. Specifically, by building large language model capabilities through our AI middleware, we enable users to independently develop intelligent applications. We have launched an intelligent agent for patient recruitment based on a medical record comprehension model, improving the efficiency of clinical trial matching and medical record data utilization. Additionally, we provide tools to empower physicians, supporting the generation of patient education content and the extraction of research insights. These innovative solutions have already delivered outstanding results in sectors such as healthcare and pharmaceuticals.

Big Data Platform and Solutions ("BDPS") (AI for Medical)

In the BDPS segment, we provide data intelligence platforms and data analytics-driven solutions for hospitals, healthcare institutions, regulators and policymakers. During the Reporting Period, the revenue of this segment was RMB153.2 million, representing a year-on-year increase of 14.6%. As of 30 September 2025, the total number of our top hospital clients was 127, while the total number of regulator and policymaker clients was 44.

During the Reporting Period, driven by the dual engines of "data elements × AI technology", we followed the logical path of "digital and intelligent transformation of renowned hospitals → in-depth specialization in specific medical fields → intelligent collaboration with experts" to build a full-chain empowerment system. On one hand, we continued to solidify the foundation of data intelligence, on the other hand, we accelerated the large-scale implementation of intelligent applications, achieving value penetration from institutions to academic disciplines and then to individuals.

In-depth Engagement with Renowned Hospitals: We continuously deepened our collaborations with well-known domestic hospitals, promoting the comprehensive construction of hospital data infrastructure and intelligent operation systems. During the Reporting Period, we assisted a top-tier hospital in East China in building a new-generation data center. Additionally, we implemented a comprehensive disease database platform, a clinical research management system and an operational intelligent agent at the Second Affiliated Hospital of Chongqing Medical University, enabling full-chain empowerment from data governance to intelligent applications and assisting public hospitals in transitioning from experience-based management to data-driven precision governance. Through our AI middleware, we facilitated a wide range of innovative applications in hospitals, the Children's Medical Center affiliated with Capital Medical University rapidly integrated knowledge bases through the AI middleware to create an AI customer service system for immediate complaint handling, providing 7×24 full-process patient consultation and popularization services.

Focus on Key Specialties: Leveraging large language model technology, we continuously built closed loops of research and application across multiple key disease specialties. In core disease areas such as oncology, hematology, ophthalmology and dermatology, we continued to deepen our professional expertise. During the Reporting Period, we won bids for projects including the development of a scientific research big data platform and a specialized disease database for a top-tier oncology hospital in North China. In the field of oncology diagnosis and treatment, the accuracy of our TNM staging assessment intelligent agent improved from 58% to 90% for T staging and from 62% to 80% for N staging, reaching the diagnostic level of chief physicians and providing strong support for precision oncology. At a leading cancer prevention and treatment center in South China, our physician Copilot now achieves nearly 1,000 daily deployments, widely covering approximately 70% of medical staff and assisting doctors in cumulatively serving over 31,000 patient consultations. We also expanded our research capabilities in fields such as respiratory, dental and traditional Chinese medicine (TCM), including participating in national key projects and research initiatives on asthma diagnosis and treatment management and TCM-based gastric cancer prevention and treatment, broadening the disciplinary boundaries of our research services.

Collaboration with Leading Experts: We are deeply integrating the clinical expertise of experts with large language model technology to create "digital avatars" of physicians, thereby further improving service for patients and refining management practices. Currently, we have collaborated with experts in fields such as cervical cancer, weight management and liver cancer to jointly advance related applications. At a top-tier comprehensive hospital in Central China, we utilized our AI middleware to create a highly realistic "AI digital avatar" for experts, providing postoperative follow-up, medication guidance and report interpretation services to patients attending follow-up consultations.

We are processing and analyzing increasingly rich and diverse data for regulatory agencies and policy makers. With authorization, we provide AI-powered data analysis-driven solutions for regulatory agencies and policy makers, covering the development of national, provincial, and municipal-level regional platforms, as well as public health initiatives. Leveraging our AI-enabled analytical tools and cutting-edge simulation models, we also assist in building urban "Health Brains" focusing on regional population health management. During the Reporting Period, we supported the Weifang Municipal Health Commission in establishing a comprehensive decision-making center and health profiling system, contributing to the reshaping of Weifang's scientific medical institution evaluation system and the development of a lifelong health management model for its residents.

Life Sciences Solutions ("LSS") (AI for Life Science)

The LSS segment is dedicated to providing AI-powered intelligent services and solutions across the entire product lifecycle for global pharmaceutical companies, biotech firms, and medical device manufacturers. Leveraging AI-powered disease models and data insights, we help our partners significantly shorten R&D cycles, optimize development costs, enhance clinical trial quality, and accelerate commercial success.

YiduTech deeply integrates AI technology into the entire clinical trial process, building an end-to-end intelligent solution. During the study design phase, intelligent analysis tools utilize multi-center data and natural language processing to rapidly generate visual analyses for patient inclusion and exclusion, facilitating protocol optimization. In patient recruitment, AI enables precise matching between real-world data and trial protocols, significantly improving enrollment efficiency and reducing screen failure rates. For data management, an intelligent entry system automates the transcription from electronic medical records to EDC systems, substantially reducing manual effort while ensuring data quality. Patient management enhances subject compliance through personalized reminders and remote monitoring. At the quality control stage, a full-process intelligent identification mechanism that automatically detects data issues has been established, enabling efficient quality management and end-to-end traceability.

During the Reporting Period, our revenue reached RMB138.3 million, a decrease of 4.4% compared to the same period of last year. We remain focused on serving high-quality clients, continuously innovating through digital and intelligent technologies. By offering intelligent solutions that span the entire product lifecycle, we enhance the customer experience, build strong client loyalty, and foster a virtuous cycle of ongoing collaboration. As of 30 September 2025, among the top 20 multinational pharmaceutical companies, 17 are our clients.

In clinical research, we have performed 483 clinical research projects, including clinical trials sponsored by pharmaceutical companies and researchers. Our portfolio of prospective and retrospective real-world research projects reached 301.

During the Reporting Period, YiduTech successfully supported several projects of significant clinical value. Leveraging our AI-driven integrated platform, we provided comprehensive market and project research and analysis support for a globally innovative topical gel for infantile hemangioma, facilitating its accelerated approval and market launch. Based on data insights and analysis from our AI platform, we formulated a precise registration strategy and efficiently completed the submission for an innovative first-in-class new drug for chronic hepatitis B, enabling it to smoothly obtain clinical approval. In the Phase III clinical trial of a biosimilar for the treatment of age-related macular degeneration, through our AI-empowered "Recruitment-Operations-SMO" integrated platform, we achieved efficient progression and high-quality completion of the trial, continuously earning customer recognition and repeat business.

During the Reporting Period, our LSS segment achieved major breakthroughs in data collaboration and research. We won bids for two major projects of the National Healthcare Security Administration, with our "AI + Healthcare Insurance" capabilities receiving recognition. We have also built a robust collaborative network involving key medical institutions, research institutes, and industry partners. Additionally, our Real-World Evidence research team made substantive progress in cutting-edge fields such as pediatric rare diseases, and thus we successfully won the bid for a real-world study commissioned by a foreign-invested group to support the CDE submission of its pediatric rare disease drug. Leveraging on the favourable pilot implementation and trial policies, we facilitated the clinical translation and application of innovative drugs, gradually establishing a closed-loop capability spanning data integration, policy research, and clinical translation.

Our team possesses an average of over 10 years of experience across various fields, including clinical research, data science, epidemiology, biostatistics, medical informatics, and artificial intelligence. By cultivating a high-caliber talent pool, we continuously enhance project operational efficiency and customer experience, ensuring we maintain a competitive edge in a highly competitive market.

Health Management Platform and Solutions ("HMPS") (AI for Care)

In this segment, we provide AI-enabled health management solutions to cater to multi-level healthcare solutions for tens of millions of urban residents. During the Reporting Period, the revenue of our HMPS segment amounted to RMB66.6 million, representing a year-on-year increase of 30.3%.

During the Reporting Period, we continued to consolidate our Hui Min Bao (惠民保) business. We enhanced our efforts in the Hui Min Bao (惠民保) projects in China's core provinces and cities. With the support of AI medical technology, the medical insights accumulated by YiduCore, and our rich experience in scenario operations, we have been able to provide and continue to innovate and upgrade one-stop operation solutions for Hui Min Bao (惠民保) in provinces and cities with tens of millions of populations such as Beijing and Shenzhen, which further solidified the advantageous position of our Hui Min Bao (惠民保) business in China's core cities.

During the Reporting Period, we were the main operation platform for Shenzhen Hui Min Bao (深圳惠民保) for three consecutive years, the number of the insured for Shenzhen Hui Min Bao (深圳惠民保) reached 6.15 million in 2025, setting record high, and the cumulative number of the insured reached 18 million in a three-year period. As of 30 September 2025, Shenzhen Hui Min Bao (深圳惠民保) has provided payouts for nearly 390,000 claims, with the highest cumulative reimbursement for a single individual reaching RMB1.75 million. In addition, we have served as the main operation platform for Beijing Hui Min Bao (北京惠民保) for five consecutive years. The cumulative number of the insured for Beijing Hui Min Bao (北京惠民保) amounted to more than 15 million, and the cumulative number of claims received has exceeded 420,000 claims, providing timely protection to numerous families affected by illness and benefiting the public in a significant way. We also provide professional customer services and claim services for "Hebei Yi Hui Bao (河北醫惠保)".

With the empowerment of AI technology, our insurance claim efficiency has been significantly improved. Over 85% of claims settled under the Beijing Hui Min Bao (北京惠民保) were compensated through express claims processing. By processing data legally authorized by the users and relevant organizations, we are able to achieve rapid processing of tens of thousands of cases per month, and the claim settlement efficiency measured by processing time has been improved by 60%–70% compared with the traditional methods. After applying the expedited claim model, the expedited claim cases do not require the insured to provide medical bills and other claim materials, but rather, with the prior consent of the user, actively reach out and notify the insured by text messages and phone calls that the claim criteria have been met and the claim can be paid, which significantly shortens the time for claim settlement and reduces the burden of advancing funds on the part of the insured, and greatly improves the experience of the insured in the use of the insurance policy. Our AI-powered customer service delivers efficient, 24/7 support with second-level accurate responses, achieving an accuracy rate of over 97%, an independent online resolution rate of 93% and good user experience as compared with the traditional services. In the future, we will adhere to improving claim efficiency through technology, enhancing claim quality through services, and exploring other claims data-enabled businesses to establish higher professional barriers.

In addition, leveraging the technological capabilities and medical knowledge accumulated within YiduCore, we deliver AI-powered, analysis-driven, one-stop solutions. These solutions deliver integrated and personalized digital therapeutics that combine traditional treatments, out-of-hospital care, and lifestyle interventions, continuously exploring new models for chronic disease management. As an AI healthcare company deeply involved in Hainan Province's "2+3" Health Services Package initiative, our digital therapeutics for diabetes have achieved remarkable results in Lingshui County, one of the initial pilot regions. Among its registered and managed diabetic patients, the compliance rate of glycated hemoglobin reached 77.91%, representing a 10.97% improvement from the baseline, significantly surpassing the provincial average. This therapeutic approach has gradually been expanded to Sanya, Wanning, Qionghai, Wenchang and other regions. As of 30 September 2025, nearly 100,000 patients have been registered and managed, with the compliance rate of fasting blood glucose increasing by 27.04% from the baseline.

As of 30 September 2025, the number of active users who have completed at least one transaction on our health management platform exceeded 22 million.

Business Outlook

To fulfill our mission of "making precision healthcare accessible to everyone" and sustain our leading position in the AI healthcare industry, we will advance in the following key directions: (i) scalable deployment of intelligent agent ecosystems: Based on our "AI Medical Brain" YiduCore, we will take the physician Copilot product matrix as the core to promote the in-depth application of intelligent agents across all healthcare scenarios, achieving automated reconstruction of medical workflows and transformation of service models to enhance medical efficiency and user experience; (ii) deepening disease research and application: We will further integrate large language models with multi-center real-world data and translate our in-depth understanding of diseases into high-value specialized disease data assets and disease models, directly empowering our product ecosystem and strengthening the professional barriers of our specialty-focused solutions; (iii) human-machine collaboration to provide professional and efficient services: We are committed to combining human expertise with AI's efficiency and precision to deliver end-to-end, high-efficiency, high-value and high-experience outcomes, improving internal operational efficiency while enhancing customer satisfaction and sense of gain; and (iv) enriching our ecosystem through strategic partnerships, investments and acquisitions.

In respect of BDPS, we will continue to strengthen our AI-enabled "two-pronged" strategy. Horizontally, we focus on "expanding the breadth of intelligence": through a continuously evolving AI product system, we will further expand our hospital and urban regional network coverage while continuously broadening the boundaries of customer application scenarios, achieving a leap from single-point tools to full-chain AI solutions. Vertically, we strive to "dig into the depth of intelligence": based on disease dimensions and hospital networks, we will continue to deepen and optimize research in various key disease areas through multi-center studies, aiming to continuously accumulate and transform data insights generated during the research process into reusable specialty disease models and products, deepening our professional advantages in key disease areas.

In respect of LSS segment, based on the continuous evolution of YiduCore, we will transition from "the production of research-grade evidence" to "the supply of decision-grade intelligence", upgrading our one-stop solutions from clinical development to post-launch commercialization. We will (i) promote the intelligent leap of the i-series solutions, integrating cutting-edge AI capabilities such as large language models into more key links, helping pharmaceutical companies reduce new drug development costs and enhance operational efficiency; (ii) deepen the strategic application of RWE; (iii) focus on key disease areas we excel at in clinical development; and (iv) build a high-value customer symbiotic system.

In respect of HMPS segment, we will continue to utilize our disease insights, knowledge and expert network to provide effective health management solutions to benefit more people with "patient-centered, outcome-oriented" care. We will continue to (i) pay more attention to the improvement of users' health-related quality of life and platform stickiness while expanding user coverage through diversified channels; (ii) fully dedicate to building a new AI-driven health management paradigm.

At the forefront of AI healthcare, we will continue to uphold our mission of "making precision healthcare accessible to everyone", persistently exploring paths for the integration of technological innovation and industrial application. Through resilient independent innovation and high-quality operations, we will deeply participate in and contribute to the global healthcare ecosystem's intelligent transformation, bringing more value to industry participants in the healthcare ecosystem.

MANAGEMENT DISCUSSION AND ANALYSIS

Revenues

Our revenues increased by 8.7% from RMB329.4 million for the six months ended 30 September 2024 to RMB358.1 million for the six months ended 30 September 2025. The increase was primarily attributable to the increase in revenue from Big Data Platform and Solutions segment and Health Management Platform and Solutions segment.

Big Data Platform and Solutions. Revenue from Big Data Platform and Solutions increased by 14.6% from RMB133.7 million for the six months ended 30 September 2024 to RMB153.2 million for the six months ended 30 September 2025. Such increase was primarily driven by expanded business opportunities resulting from policy tailwinds.

Life Sciences Solutions. Revenue from Life Sciences Solutions remained relatively stable with a decrease of 4.4% from RMB144.6 million for the six months ended 30 September 2024 to RMB138.3 million for the six months ended 30 September 2025.

Health Management Platform and Solutions. Revenue from Health Management Platform and Solutions increased by 30.3% from RMB51.1 million for the six months ended 30 September 2024 to RMB66.6 million for the six months ended 30 September 2025, mainly due to the change in product mix.

Cost of Sales and Services

Our cost of sales and services increased by 5.6% from RMB212.1 million for the six months ended 30 September 2024 to RMB224.1 million for the six months ended 30 September 2025.

Big Data Platform and Solutions. Cost of sales and services from the Big Data Platform and Solutions segment increased by 5.2% from RMB83.7 million for the six months ended 30 September 2024 to RMB88.0 million for the six months ended 30 September 2025, primarily due to the growth resulting from the increase in order deliveries.

Life Sciences Solutions. Cost of sales and services from Life Sciences Solutions remained relatively stable with a decrease of 1.1% from RMB101.7 million for the six months ended 30 September 2024 to RMB100.6 million for the six months ended 30 September 2025.

Health Management Platform and Solutions. Cost of sales and services from the Health Management Platform and Solutions segment increased by 32.7% from RMB26.7 million for the six months ended 30 September 2024 to RMB35.5 million for the six months ended 30 September 2025, which was mainly due to a roughly proportional increase in revenue.

Gross profit and gross margin

As a result of the foregoing, our overall gross profits for the six months ended 30 September 2024 and 2025 were RMB117.4 million and RMB134.0 million respectively, and our overall gross margins were 35.6% and 37.4% respectively.

Big Data Platform and Solutions. Our gross margin in Big Data Platform and Solutions increased from 37.4% for the six months ended 30 September 2024 to 42.5% for the six months ended 30 September 2025, primarily due to the change in product mix.

Life Sciences Solutions. Our gross margin in Life Sciences Solutions remained relatively stable with a decrease from 29.7% for the six months ended 30 September 2024 to 27.2% for the six months ended 30 September 2025.

Health Management Platform and Solutions. Our gross margin in Health Management Platform and Solutions remained relatively stable with a decrease from 47.8% for the six months ended 30 September 2024 to 46.8% for the six months ended 30 September 2025.

Selling and marketing expenses

Our selling and marketing expenses remained relatively stable with an increase of 1.5% from RMB72.4 million for the six months ended 30 September 2024 to RMB73.5 million for the six months ended 30 September 2025.

Selling and marketing expenses as a percentage of revenue decreased from 22.0% for the six months ended 30 September 2024 to 20.5% for the six months ended 30 September 2025.

Administrative expenses

Our administrative expenses remained stable with an increase of 5.5% from RMB57.2 million for the six months ended 30 September 2024 to RMB60.4 million for the six months ended 30 September 2025.

Administrative expenses as a percentage of revenue decreased from 17.4% for the six months ended 30 September 2024 to 16.9% for the six months ended 30 September 2025.

Research and development expenses

Our research and development expenses decreased by 9.5% from RMB93.7 million for the six months ended 30 September 2024 to RMB84.8 million for the six months ended 30 September 2025, mainly attributable to the decrease in technical and consultancy service fees from RMB26.8 million to RMB14.6 million.

Research and development expenses as a percentage of revenue decreased from 28.4% for the six months ended 30 September 2024 to 23.7% for the six months ended 30 September 2025.

Operating loss

As a result of the foregoing, operating loss generated from the Group decreased by 71.0% from RMB54.3 million for the six months ended 30 September 2024 to RMB15.7 million for the six months ended 30 September 2025.

Taxation

Income tax of the Group increased from the income tax credit of RMB32 thousand for the six months ended 30 September 2024 to the income tax expense of RMB2 thousand for the six months ended 30 September 2025.

Loss for the period

As a result of the foregoing, our loss for the period decreased by 72.0% from RMB56.4 million for the six months ended 30 September 2024 to RMB15.8 million for the six months ended 30 September 2025.

Liquidity and capital resource

For the six months ended 30 September 2025, we had funded our cash requirements principally from capital contribution from shareholders and financing through issuance and sales of convertible redeemable preferred shares in private placement transactions and proceeds from initial public offering. We had cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balance and deposits of RMB3,309.1 million and RMB2,099.3 million as at 31 March 2025 and 30 September 2025 respectively.

Significant Equity Investments

On 28 October 2022, Marvelous Panda Inc., a wholly-owned subsidiary of the Company, entered into a subscription agreement for the fund YD Capital I L.P. (the "**Fund**") with the general partner and became a limited partner of the Fund by making a cash contribution of US$40.0 million to the Fund, representing 40% of the fund commitment. As at 30 September 2025, the cash equivalent to US$13.2 million was paid by the Group. The purpose of the Fund is primarily to (i) make venture capital investments in the healthcare sector; (ii) manage, supervise and dispose of such investments; and (iii) engage in such other activities incidental or ancillary thereto as the general partner deems necessary, appropriate or advisable.

Material acquisitions and disposals

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies for the six months ended 30 September 2025.

Pledge of assets

As at 30 September 2025, the Group had no material pledge of assets.

Future plans for material investments or capital assets

As at 30 September 2025, the Group did not have detailed future plans for material investments or capital assets.

Foreign exchange exposure

During the Reporting Period, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of our Company and subsidiaries operating outside the PRC, the subsidiaries and the consolidated affiliated entities that operate in the PRC, are U.S. dollar, Renminbi, respectively. During the six months ended 30 September 2025, we had currency translation losses of RMB33.4 million and net foreign exchange losses of RMB1.9 million, as compared with currency translation losses of RMB39.6 million and net foreign exchange gains of RMB2.1 million during the six months ended 30 September 2024. We did not hedge against any fluctuation in foreign currency during the six months ended 30 September 2024 and 2025.

Contingent liabilities

As at 30 September 2025, we did not have any material contingent liabilities (as at 31 March 2025: nil).

Capital commitment

As at 30 September 2025, capital commitment of the Group was nil (as at 31 March 2025: nil).

Investment commitment

As at 30 September 2025, investment commitment of the Group was RMB200.6 million (as at 31 March 2025: RMB249.0 million), mainly for the outstanding contribution from Marvelous Panda Inc., a wholly-owned subsidiary of the Company, to the Fund YD Capital I L.P.

Employees and remuneration

As at 30 September 2025, the Group had a total of 699 employees, with 351 employees based in Beijing, 76 employees based in Shanghai and 272 employees based in offices in other cities in China and overseas. The following table sets forth the total number of employees by function as at 30 September 2025:

Function	**Number of employees**
Product Development and Technology	306
Medical Function	216
Sales and Marketing	115
General and Administrative	62
Total	**699**

The total remuneration cost incurred by the Group for the six months ended 30 September 2025 was RMB188.7 million, as compared to RMB187.7 million for the six months ended 30 September 2024. The Company has also adopted and amended a post-IPO share award scheme and adopted a post-IPO share option scheme which was terminated on 25 August 2023 but the provisions of the post-IPO share option scheme shall remain in full force to the extent necessary to give effect to the exercise of any options granted prior to the termination.

Subsequent Events

As of the date of this announcement, no significant events occurred after the Reporting Period which require additional disclosures or adjustments.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability, and the shares of the Company were listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 15 January 2021.

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders and to enhance corporate value and accountability.

Compliance with the Code on Corporate Governance Practices

During the Reporting Period, the Company has complied with the applicable provisions of the Corporate Governance Code (the "**Corporate Governance Code**") set out in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 of the Listing Rules as its own code of conduct regarding directors' securities transactions.

Specific enquiry has been made of all the Directors and the relevant employees and they have confirmed that they have complied with the Model Code during the Reporting Period.

Audit Committee

The Group has established an audit committee comprising three members, being Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi, with Ms. Pan Rongrong (being the Company's independent non-executive Director with the appropriate professional qualifications) as chair of the audit committee.

The audit committee has reviewed the consolidated financial statements of the Group for the six months ended 30 September 2025 and has met with the independent auditor, PricewaterhouseCoopers. The audit committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control and financial reporting matters with senior management members of the Company.

Auditor's scope of work

The Company's external auditor, PricewaterhouseCoopers, has performed a review of the Group's unaudited interim condensed consolidated financial information for the six months ended 30 September 2025 in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". PricewaterhouseCoopers confirmed that nothing has come to their attention that causes them to believe that the interim financial information is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

OTHER INFORMATION

Purchase, sale or redemption of the Company's listed securities

During the Reporting Period, the Company repurchased a total of 688,000 shares of the Company on the Stock Exchange at an aggregate consideration of approximately HK$3,926,278.45 and held as treasury shares of the Company. The repurchase was effected for the enhancement of shareholder value in the long term.

Particulars of the shares repurchased are as follows:

Month of Repurchase	No. of Shares Repurchase	Price Paid per Share Highest *(HK$)*	Lowest *(HK$)*	Aggregate Consideration *(HK$)*
September	688,000	5.79	5.57	3,926,278.45
Total	**688,000**			**3,926,278.45**

Material litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the Reporting Period and up to the date of this announcement.

Use of proceeds from global offering

On 15 January 2021, the shares of the Company were listed on the Main Board of the Stock Exchange. The net proceeds from the global offering (following full exercise of the Over-allotment Option, as defined in the prospectus of the Company dated 31 December 2020 (the "**Prospectus**")) were approximately HK$3,825 million (the "**Net Proceeds**"), which are intended to be applied in the manner set out in the Prospectus. There was no change in the intended use of proceeds as previously disclosed.

Set out below is the status of use of proceeds from the global offering as at 30 September 2025.

Purpose	**% of use of proceeds**	**Net proceeds** *(RMB million)*	**Unutilised amount as at 31 March 2025** *(RMB million)*	**Amount used for the six months ended 30 September 2025** *(RMB million)*	**Unutilised amount as at 30 September 2025** *(RMB million)*	**Actual/expected time of full utilisation**
Strengthen our core capabilities	35%	1,339	239	120	119	31 March 2026
Further our business expansion	35%	1,339	—	—	—	30 September 2024
Further enrich our ecosystem through strategic partnerships, investments and acquisitions	20%	765	701	66	635	31 March 2030
Working capital and general corporate purposes	10%	382	—	—	—	31 March 2025

The above Net Proceeds were translated with spot rates on the Listing Date, while the cash and cash equivalents, term deposits, restricted bank balance and deposits as of 30 September 2025 were translated with spot rates on its balance sheet date.

As at 30 September 2025, the Company had utilised RMB3,071 million of the Net Proceeds.

Interim dividend

The Board does not recommend the distribution of an interim dividend for the six months ended 30 September 2025.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Six months ended 30 September	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers	**358,105**	329,448
Cost of sales and services	**(224,078)**	(212,098)
Gross profit	**134,027**	117,350
Selling and marketing expenses	**(73,493)**	(72,435)
Administrative expenses	**(60,375)**	(57,240)
Research and development expenses	**(84,785)**	(93,682)
Net impairment losses on financial assets and contract assets	**(36,565)**	(33,966)
Impairment of non-financial assets	**17**	100
Other income	**80,916**	82,937
Other gains — net	**24,539**	2,663
Operating loss	**(15,719)**	(54,273)
Finance income	**2,022**	1,089
Finance costs	**(940)**	(675)
Finance income — net	**1,082**	414
Share of losses from investments in associates	**(1,121)**	(2,535)
Loss before income tax	**(15,758)**	(56,394)
Income tax (expense)/credit	**(2)**	32
Loss for the period	**(15,760)**	(56,362)
Loss is attributable to:		
Owners of the Company	**(14,602)**	(43,446)
Non-controlling interests	**(1,158)**	(12,916)
	(15,760)	(56,362)

	Six months ended 30 September	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other comprehensive income		
Item that will not be reclassified to profit or loss:		
Currency translation differences	**(71,940)**	131,098
Item that will be reclassified to profit or loss:		
Currency translation differences	**38,529**	(170,735)
Other comprehensive loss for the period, net of tax	**(33,411)**	(39,637)
Total comprehensive loss for the period	**(49,171)**	(95,999)
Total comprehensive loss for the period is attributable to:		
Owners of the Company	**(46,993)**	(85,528)
Non-controlling interests	**(2,178)**	(10,471)
	(49,171)	(95,999)
Loss per share, basic and diluted *(RMB)*	**(0.01)**	(0.04)

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

	As at 30 September 2025 *RMB'000* (Unaudited)	As at 31 March 2025 *RMB'000* (Audited)
Assets		
Non-current assets		
Property, plant and equipment	**149,739**	156,941
Right-of-use assets	**4,645**	5,588
Investment properties	**3,332**	2,894
Intangible assets	**33,225**	33,953
Deferred income tax assets	**29**	30
Investments accounted for using the equity method	**84,687**	39,428
Investments measured at amortized cost	**1,428,206**	366,088
Financial assets at fair value through profit or loss	**72,497**	104,427
Pledged bank deposits	**6,436**	6,439
Restricted bank balance and deposits	**6,337**	6,352
Total non-current assets	**1,789,133**	722,140
Current assets		
Inventories	**34,699**	12,902
Trade receivables	**428,864**	449,239
Contract assets	**59,273**	69,753
Other financial assets at amortized cost	**19,215**	45,679
Investments measured at amortized cost	**23,189**	9,598
Financial assets at fair value through profit or loss	**131,318**	17,000
Pledged bank deposits	**3,009**	3,217
Restricted bank balance and deposits	**2,225**	37,570
Term deposits	**856,471**	1,939,134
Cash and cash equivalents	**1,224,826**	1,316,397
Other current assets	**84,866**	66,483
Total current assets	**2,867,955**	3,966,972
Total assets	**4,657,088**	4,689,112

	As at 30 September 2025 *RMB'000* (Unaudited)	As at 31 March 2025 *RMB'000* (Audited)
Equity		
Equity attributable to owners of the Company		
Share capital	**137**	136
Treasury shares	**(17,298)**	(13,710)
Other reserves	**13,093,590**	13,113,631
Accumulated losses	**(9,193,350)**	(9,178,748)
	3,883,079	3,921,309
Non-controlling interests	**54,255**	56,433
Total equity	**3,937,334**	3,977,742
Liabilities		
Non-current liabilities		
Lease liabilities	**4,993**	5,551
Deferred income	**66,473**	69,742
Total non-current liabilities	**71,466**	75,293
Current liabilities		
Borrowings	**124,002**	121,997
Trade and other payables	**297,638**	253,488
Salary and welfare payable	**154,331**	177,805
Contract liabilities	**68,696**	68,734
Current income tax liabilities	**234**	234
Lease liabilities	**1,738**	1,996
Provisions	**1,649**	11,823
Total current liabilities	**648,288**	636,077
Total liabilities	**719,754**	711,370
Total equity and total liabilities	**4,657,088**	4,689,112

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL DATA

1 General information

Yidu Tech Inc. (the "**Company**") was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability under the Companies Act of the Cayman Islands (Cap. 22, Law 3 of 1961 as consolidated and revised). The address of the Company is Suite#4–210, Governors Square, 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands.

The Company is an investment holding company and its subsidiaries (together, the "**Group**") are primarily engaged in the provision of the following services: i) big data platform and solutions; ii) life sciences solutions; and iii) health management platform and solutions in the People's Republic of China ("**PRC**") and Brunei.

The interim condensed consolidated financial information comprises the interim condensed consolidated balance sheet as at 30 September 2025, the interim condensed consolidated statement of comprehensive income, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and selected explanatory notes (the "**Interim Financial Information**").

The Interim Financial Information is presented in Renminbi ("**RMB**"), unless otherwise stated.

2 Basis of preparation

The Interim Financial Information for the six months ended 30 September 2025 has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" ("**IAS 34**").

The Interim Financial Information does not include all the notes of normally included in an annual consolidated financial statements. Accordingly, it should be read in conjunction with the Group's consolidated financial statements for the year ended 31 March 2025.

3 Material accounting policies

The accounting policies applied to the preparation of the Interim Financial Information are consistent with those applied in the preparation of the Group's consolidated financial statements for the year ended 31 March 2025.

3 Material accounting policies (continued)

In addition, certain new and amended standards and annual improvements have been published that are not mandatory for the current reporting period and have not been early adopted by the Group. As disclosed in the annual consolidated financial statements for the year ended 31 March 2025, the adoption of IFRS 18 Presentation and Disclosure in Financial Statements, effective for annual periods beginning on or after 1 January 2027, will impact the presentation and disclosure, in particular those related to the statement of financial performance and providing management-defined performance measures within the financial statements.

Management is currently assessing the implication of applying IFRS 18, and preliminarily identified the fair value gains/(losses) on financial assets currently presented in the line item 'Other gains-net' within operating profit would be presented below operating profit, and certain additional disclosures would be added, other than that, there would not be significant impact on the Group's financial position and performance when adopting IFRS 18.

Apart from IFRS 18, other new and amended standards and annual improvements are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions.

4 Critical accounting estimates and judgements

The preparation of the Interim Financial Information requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing the Interim Financial Information, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied in the preparation of the Group's consolidated financial statements for the year ended 31 March 2025.

5 Segment information

Disaggregation of revenue from contracts with customers

The Group's business activities, for which discrete financial statements are available, are regularly reviewed and evaluated by the Chief Operating Decision Maker. As a result of this evaluation, the Group determined that it has operating segments as follows:

- Big data platform and solutions
- Life sciences solutions
- Health management platform and solutions

5 Segment information (continued)

	Six months ended 30 September 2025 (Unaudited)			
	Big data platform and solutions *RMB'000*	**Life sciences solutions** *RMB'000*	**Health management platform and solutions** *RMB'000*	**Total** *RMB'000*
Revenue from contracts with customers	**153,180**	**138,253**	**66,672**	**358,105**
Cost of sales and services	**(88,024)**	**(100,595)**	**(35,459)**	**(224,078)**
Gross profit	**65,156**	**37,658**	**31,213**	**134,027**

	Six months ended 30 September 2024 (Unaudited)			
	Big data platform and solutions *RMB'000*	Life sciences solutions *RMB'000*	Health management platform and solutions *RMB'000*	Total *RMB'000*
Revenue from contracts with customers	133,670	144,617	51,161	329,448
Cost of sales and services	(83,650)	(101,717)	(26,731)	(212,098)
Gross profit	50,020	42,900	24,430	117,350

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the PRC. For the six months ended 30 September 2025 and 2024, the Group earns approximately 87% and 13%, 85% and 15% of total revenue from external customers located in the PRC and other countries, respectively.

As at 30 September 2025 and 31 March 2025, majority of the non-current assets of the Group were located in the PRC and Brunei.

6 Expenses by nature

Expenses included in cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses are further analysed as follows:

	Six months ended 30 September	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefits expenses	**188,731**	187,678
Outsourcing services fee	**121,902**	106,728
Cost of hardware and medicine	**49,108**	34,628
Consulting and other professional fee	**27,327**	40,567
Travelling, entertainment and general office expenses	**22,657**	26,720
Depreciation of property, plant and equipment	**14,183**	13,132
Promotion and advertising expenses	**7,852**	8,095
Amortization of intangible assets	**3,732**	4,835
Labour dispatching	**2,402**	2,559
Auditors' remuneration	**1,683**	3,153
— *Auditor of the Company*	**1,000**	1,600
Depreciation of right-of-use assets	**1,012**	4,866
Taxes and surcharges	**989**	1,049
Other expenses	**1,153**	1,445
Total cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses	**442,731**	435,455

7 Income tax expense/(credit)

	Six months ended 30 September	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax expense	**1**	—
Deferred income tax expense/(credit)	**1**	(32)
Income tax expense/(credit)	**2**	(32)

Income tax expense is recognized based on the management's best knowledge of the income tax rates that would be applicable to the full financial year.

8 Loss per share

Basic loss per share is calculated by dividing the loss attributable to the Company's owners by the weighted average number of ordinary shares in issue during the six months ended 30 September 2025 and 2024.

The calculation of loss per share is based on the following:

	Six months ended 30 September	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss attributable to owners of the Company	**(14,602)**	(43,446)
Weighted average number of ordinary shares in issue *('000)*	**1,060,170**	1,057,401
Basic loss per share *(RMB yuan)*	**(0.01)**	(0.04)

9 Trade receivables

	As at 30 September 2025	As at 31 March 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables from contracts with customers		
— Third parties	**656,281**	654,180
Less: allowance for impairment of trade receivables	**(227,417)**	(204,941)
	428,864	449,239

9 Trade receivables (continued)

(a) The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 180 days. The aging analysis of the trade receivables based on invoice date is as follows:

	As at 30 September 2025 ***RMB'000*** **(Unaudited)**	As at 31 March 2025 *RMB'000* (Audited)
— Up to 3 months	**194,293**	196,517
— 3 to 6 months	**42,336**	51,680
— 6 months to 1 year	**116,063**	81,400
— 1 to 2 years	**103,947**	188,541
— 2 to 3 years	**106,044**	54,030
— Over 3 years	**93,598**	82,012
	656,281	654,180
Less: allowance for impairment of trade receivables	**(227,417)**	(204,941)
	428,864	449,239

(b) Fair values of trade receivables

Due to the short-term nature of the current receivables, their carrying amounts are considered to be approximately the same as their fair values.

10 Trade and other payables

	As at 30 September 2025	As at 31 March 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables (a)	**156,151**	137,269
Tax payables	**11,438**	11,687
Notes payables	**15,129**	4,520
Other payables:		
— Insurance premium collection payables (b)	**589**	3,829
— Payables for consulting and other service fee	**24,568**	28,418
— Insurance claims collection payables (c)	**51,839**	26,681
— Payables for repurchase of options	**11,112**	11,226
— Reimbursement payable to employees	**5,003**	6,654
— Accrual for marketing and sales promotion expenses	**3,146**	4,033
— Payables for leasehold improvement	**2,800**	4,783
— Payables for purchase of fixed assets and intangible assets	**509**	570
— Others	**15,354**	13,818
	297,638	253,488

The carrying amounts of trade and other payables are considered to be approximated to their fair values, due to their short-term nature.

10 Trade and other payables (continued)

(a) The aging analysis of the trade payables based on invoice or accrual date at the end of each reporting period are as follows:

	As at 30 September 2025 *RMB'000* **(Unaudited)**	As at 31 March 2025 *RMB'000* (Audited)
— Up to 3 months	**67,438**	57,088
— 3 to 6 months	**6,364**	1,921
— 6 months to 1 year	**21,601**	7,598
— 1 to 2 years	**20,683**	26,559
— 2 to 3 years	**3,975**	9,635
— Over 3 years	**36,090**	34,468
	156,151	137,269

(b) Insurance premium collection payables are insurance premiums collected on behalf of insurance companies but not yet remitted to them as at 30 September 2025.

(c) Insurance claims collection payables are insurance premiums that have been collected from insurance companies but have not yet been paid to third parties as at 30 September 2025.

11 Dividend

No dividend has been paid or declared by the Company or the companies now comprising the Group during the six months ended 30 September 2025 and 2024.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.yidutech.com). The interim report of the Group for the six months ended 30 September 2025 will be dispatched to the Company's shareholders and made available for review on the same websites in due course.

By order of the Board
Yidu Tech Inc.
Gong Yingying
Executive Director and Chairlady

Hong Kong, 27 November 2025

As at the date of this announcement, the executive Directors are Ms. Gong Yingying, Mr. Xu Jiming, Ms. Feng Xiaoying, and Dr. Xie Li; the non-executive Director is Mr. Zeng Ming; and the independent non-executive Directors are Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi.